絞り込み

16530

広告

Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism.

著者 Riva N , Puljak L , Moja L , Ageno W , Schünemann H , Magrini N , Squizzato A
J Clin Epidemiol.2017 Nov 21 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (103view , 0users)

Full Text Sources

Miscellaneous

To explore disagreements in multiple systematic reviews (SRs) assessing the benefit-to-harm ratio of thrombolytic therapy in patients with intermediate-risk pulmonary embolism (PE).
PMID: 29175415 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード